Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Abeona Therapeutics Inc ABEO

Healthcare Biotechnology
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The... see more

Recent & Breaking News (NDAQ:ABEO)

Abeona Therapeutics Appoints Dr. Victor Paulus Senior Vice President of Regulatory Affairs

GlobeNewswire June 26, 2019

Abeona Therapeutics Appoints Dr. Victor Paulus Senior Vice President of Regulatory Affairs

Thomson Reuters ONE June 26, 2019

Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease

GlobeNewswire June 18, 2019

Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease

Thomson Reuters ONE June 18, 2019

Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease

Thomson Reuters ONE May 21, 2019

Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)

GlobeNewswire May 14, 2019

Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)

Thomson Reuters ONE May 14, 2019

Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights

GlobeNewswire May 10, 2019

Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights

Thomson Reuters ONE May 10, 2019

Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting

GlobeNewswire May 8, 2019

Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting

Thomson Reuters ONE May 8, 2019

Abeona Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire May 7, 2019

Abeona Therapeutics Reports Preclinical Data Demonstrating Broad Therapeutic Potential of AIM(TM) Gene Therapy in Retinal Diseases at Association for Research in Vision and Ophthalmology Annual Meeting

Thomson Reuters ONE May 1, 2019

Abeona Therapeutics Reports Preclinical Data Demonstrating Broad Therapeutic Potential of AIM(TM) Gene Therapy in Retinal Diseases at Association for Research in Vision and Ophthalmology Annual Meeting

GlobeNewswire May 1, 2019

Abeona Therapeutics to Report New Preclinical Data Demonstrating Therapeutic Potential of ABO-401 for Treatment of Cystic Fibrosis at American Society of Gene and Cell Therapy Annual Meeting

Thomson Reuters ONE April 30, 2019

Abeona Therapeutics to Report New Preclinical Data Demonstrating Therapeutic Potential of ABO-401 for Treatment of Cystic Fibrosis at American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire April 30, 2019

Abeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire April 15, 2019

Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

GlobeNewswire April 4, 2019

Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

GlobeNewswire March 18, 2019

72 Biggest Movers From Yesterday

Benzinga.com  February 26, 2019